Elite Pharmaceuticals (ELTP)
(Delayed Data from OTC)
$0.49 USD
-0.02 (-4.78%)
Updated Aug 1, 2025 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELTP 0.49 -0.02(-4.78%)
Will ELTP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELTP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELTP
The Zacks Analyst Blog Highlights Cisco Systems, Caterpillar, Charles Schwab and Elite Pharmaceuticals
Top Analyst Reports for Cisco, Caterpillar & Charles Schwab
ELTP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elite Pharmaceuticals Stock Dips Despite Record FY25 Revenue Jump
Zacks Market Edge Highlights: Elite Pharmaceuticals and Frequency Electronics
2 Defensive American Small Cap Stocks for 2025
Other News for ELTP
Elite Pharmaceuticals Inc (ELTP) Q4 2025 Earnings Call Highlights: Revenue Surge Amidst ...
Q4 2025 Elite Pharmaceuticals Inc Earnings Call Transcript
Elite Pharmaceuticals, Inc. (ELTP) Q4 2025 Earnings Call Transcript
Elite Pharmaceuticals (ELTP) Reports 48% Revenue Jump in Fiscal Year
Elite Pharmaceuticals reports FY results